Approval · Notice of Compliance 19323 · 2017
EYLEA: Notice of Compliance 19323
Issued May 19, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19323
- Date
- May 19, 2017
- Company
- Bayer Inc.Elkhart, Indiana, United States
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: eylea (aflibercept solution for intravitreal injection ) is indicated for the treatment of myopic choroidal neovascularisation (myopic cnv)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EYLEA | Not yet assigned | — |
Medicinal ingredients
- AFLIBERCEPT 40 MG per ML